NOW APPROVED: An orally-delivered small molecule compound. READ MORE >>
An orally-delivered small molecule compound that we are developing for the treatment of type 1 and type 2 diabetes. READ MORE >>
We are a biopharmaceutical company focused on the development of breakthrough treatments for human disease.READ MORE >>
At Lexicon, our passion and dedication is driven by the patients we work for. Come be a part of our multitalented team. READ MORE >>